20C2 [4H12:20C2.G6.C9]細胞
ATCC Number： CRL-2382?
細胞形態(tài)： **樣
**類型： IgG1
運輸方式： 凍存運輸
數(shù)量： 大量
生長狀態(tài)： 懸浮生長
是否是腫瘤細胞： 0
物種來源： 大鼠
Designations: 20C2 [4H12:20C2.G6.C9]
20C2 [4H12:20C2.G6.C9]細胞Depositors: DH Presky
Isotype: IgG1
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human interleukin 12 (IL-12) p75
Permits/Forms: 20C2 [4H12:20C2.G6.C9]細胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: The hybridoma cell line 20C2 [4H12:20C2.G6.C9} was established by Richard Chizzonite in 1991 and subcloned three times by limiting dilution.
The hybridoma produces an antibody (IgG1) that binds the p75 heterodimer of human IL-12.
The antibody may be used in neutralizing and receptor binding assays; it will immunoprecipitate IL-12.
The antibody can be used as a capture antibody in sandwich EIA to detect the p75 form of human IL-12.
The 20C2 antibody does not bind the p40 or p35 subunits of IL-12.
The 20C2 cell line was formed by the fusion of NSO mouse myeloma cells with splenocytes from a Lewis rat inoculated with partially purified human IL-12 p75. [38686]
Propagation: ATCC complete growth medium: Iscove's Modified Dulbecco's Medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 0.1 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%.
20C2 [4H12:20C2.G6.C9]細胞Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2020
References: 25320: Chua AO, et al. Expression cloning of a human IL-12 receptor component--a new member of the cytokine receptor superfamily with strong homology to gp130. J. Immunol. 153: 128-136, 1994. PubMed: 7911493
38686: Chizzonite R, et al. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J. Immunol. 147: 1548-1556, 1991. PubMed: 1715362
38687: Chizzonite R, et al. IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J. Immunol. 148: 3117-3124, 1992. PubMed: 1578138
38695: Desai BB, et al. IL-12 receptor. II. 20C2 [4H12:20C2.G6.C9]細胞Distribution and regulation of receptor expression. J. Immunol. 148: 3125-3132, 1992. PubMed: 1578139
38701: Gately MK, et alMeasurement of Human and Mouse Interleukin-12In: Gately MK, et alCurrent Protocols in ImmunologyNew York, N.Y.John Wiley and Sons1995.
